Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Corbus Pharmaceuticals Holdings Inc. Jumped Today

By Brian Feroldi - Updated Oct 19, 2017 at 11:56AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares rally after the company reports encouraging results from a phase 2 trial.

What happened

In response to upbeat results released from a phase 2 clinical trial, shares of Corbus Pharmaceuticals (CRBP 1.05%), a clinical-stage biotech focused on inflammatory and fibrotic diseases, jumped by 14% as of 11 a.m. EDT on Thursday.

So what

Corbus announced topline results from a 16-week phase 2 study evaluating its lead compound anabasum as a hopeful treatment for dermatomyositis, a rare disease that affects about 70,000 Americans each year.

The study showed that patients who used anabasum show an improvement on the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) activity score of 9.3 points. That was a statistically significant gain when compared to the 3.7 point improvement observed in the placebo group.

What's more, anabasum was well tolerated by users and no side effects were observed.

Female doctor giving thumbs up

Image source: Getty Images.

Yuval Cohen, CEO of Corbus, offered investors the following commentary on the study:

These trial results mark the third time anabasum has demonstrated a clear signal of clinical benefit with a favorable safety profile in a rare, inflammatory disease, having done so recently in both systemic sclerosis and cystic fibrosis. We view these data as a strong validation of the unique mechanism of action of anabasum as the potential first non-immunosuppressive pro-resolving drug to target inflammation and fibrosis. Our focus now turns to successfully executing a clinical development plan aimed at bringing anabasum to the market as expeditiously as possible.

Given the upbeat clinical news, it is easy to understand why traders are cheering today.

Now what

While dermatomyositis is a possible disease-state target for investors to watch closely, Corbus also boasts two more advanced clinical trials that are studying anabasum as a hopeful treatment for systemic sclerosis and cystic fibrosis. The company already announced plans to kick off late-stage studies in those two disease states this quarter. If all goes well with each of its trials, Corbus could have a blockbuster drug on its hands.

Does anabasum's huge potential make Corbus' stock a buy today? While I'm certainly hopeful that anabasum is the real deal, my personal preference is to keep companies like Corbus on my watchlist until we have more robust phase 3 data in hand. The reason is that I've seen way too many once-promising companies implode after data from a larger study become available. For that reason, I think the smart move for now is to monitor Corbus' progress from the sidelines.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Corbus Pharmaceuticals Holdings, Inc. Stock Quote
Corbus Pharmaceuticals Holdings, Inc.
$0.27 (1.05%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.